APP 018Alternative Names: APP-018; D-4F
Latest Information Update: 09 Jul 2007
At a glance
- Originator BruinPharma
- Class Cardiovascular therapies
- Mechanism of Action Apolipoprotein A I stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 22 Feb 2005 Phase-I clinical trials in Atherosclerosis in USA (PO)